Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass.

MLA

Serraino, Giuseppe Filiberto, et al. “Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass.” Journal of Clinical Medicine, vol. 13, no. 10, May 2024, p. 2943. EBSCOhost, https://doi.org/10.3390/jcm13102943.

APA

Serraino, G. F., Bolignano, D., Jiritano, F., Coppolino, G., Napolitano, D., Zicarelli, M., Pizzini, P., Cutrupi, S., Testa, A., Spoto, B., Andreucci, M., Mastroroberto, P., & Serra, R. (2024). Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass. Journal of Clinical Medicine, 13(10), 2943. https://doi.org/10.3390/jcm13102943

Chicago

Serraino, Giuseppe Filiberto, Davide Bolignano, Federica Jiritano, Giuseppe Coppolino, Désirée Napolitano, Mariateresa Zicarelli, Patrizia Pizzini, et al. 2024. “Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass.” Journal of Clinical Medicine 13 (10): 2943. doi:10.3390/jcm13102943.